Phase II, Open-Label Trial of Single-Agent CCNU in Dogs with Previously Untreated Histiocytic Sarcoma
Open Access
- 14 September 2010
- journal article
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 24 (6) , 1528-1531
Abstract
Background: Histiocytic sarcoma (HS) is an aggressive neoplasm in dogs, and in most instances, the disease is localized, but not amenable to surgical removal, or is disseminated. Affected patients usually die within 6 months. There have been no prospective studies to determine efficacy of single‐agent chemotherapy in dogs with HS. Hypothesis: Single‐agent CCNU [1‐(2‐chloroethyl)3‐cyclohexyl‐1‐nitrosourea; lomustine] has antitumor activity against HS in dogs. Animals: Twenty‐one dogs with histologically confirmed, nonresectable localized or disseminated HS. Methods: Prospective, open‐label phase II clinical trial in which dogs with previously untreated HS were uniformly treated with CCNU as a single oral dosage of 90 mg/m2 every 4 weeks. The primary outcome measure was reduction in tumor size. Results: Fourteen dogs with disseminated HS and 7 with localized HS were enrolled between 1999 and 2008. Overall response rate was 29% (95% confidence interval [CI], 14–50%) for a median of 96 days (95% CI, 55–137 days). Three dogs (1 disseminated, 2 localized) had complete responses lasting for 54–269 days and 3 dogs (2 disseminated, 1 localized) had partial responses lasting for 78–112 days. Conclusions and Clinical Importance: CCNU, when used as a single agent, has activity against HS in dogs. Evaluation of CCNU postoperatively for dogs with resectable localized HS and as part of combination therapy for tumors that are nonresectable or disseminated should be considered.Keywords
This publication has 7 references indexed in Scilit:
- Epidemiology, Pathology, and Genetics of Histiocytic Sarcoma in the Bernese Mountain Dog BreedJournal of Heredity, 2009
- Long‐term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy*Veterinary and Comparative Oncology, 2009
- CCNU for the Treatment of Dogs with Histiocytic SarcomaJournal of Veterinary Internal Medicine, 2007
- Localized and Disseminated Histiocytic Sarcoma of Dendritic Cell Origin in DogsVeterinary Pathology, 2002
- Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumorsCancer Chemotherapy and Pharmacology, 1997
- Malignant Histiocytosis with Multiple Skin Lesions in a Dog.Journal of Veterinary Medical Science, 1993
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961